FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

5 results

orenitram
(treprostinil)
United Therapeutics Corporation
Usage: Orenitram is indicated for treating pulmonary arterial hypertension (PAH) to delay disease progression and improve exercise capacity, primarily in patients with WHO functional class II-III symptoms, including idiopathic, heritable, or connective tissue disease-associated PAH.
remodulin
(treprostinil)
United Therapeutics Corporation
Usage: Remodulin is used to treat pulmonary arterial hypertension (PAH) to alleviate symptoms during exercise in patients with NYHA Functional Class II-IV. It is also indicated for those transitioning from epoprostenol to reduce clinical deterioration. Indications include idiopathic, heritable PAH, congenital shunts, and connective tissue diseases.
tyvaso
(treprostinil)
United Therapeutics Corporation
Usage: Tyvaso is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise ability in patients, especially those with NYHA Functional Class III symptoms. It is also approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD), enhancing exercise capacity in affected patients.
tyvaso dpi
(treprostinil)
United Therapeutics Corporation
Usage: Tyvaso DPI is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in patients, particularly those with NYHA Functional Class III symptoms. It is also indicated for pulmonary hypertension associated with interstitial lung disease (PH-ILD) to enhance exercise capacity.
veletri
(epoprostenol)
Actelion Pharmaceuticals US, Inc.
Usage: VELETRI is indicated for treating pulmonary arterial hypertension (PAH) (WHO Group 1) to enhance exercise capacity, primarily in patients with NYHA Functional Class III–IV symptoms, including idiopathic or heritable PAH and PAH linked to connective tissue diseases.

Prostacycline Vasodilator class drugs

orenitram

remodulin

tyvaso

tyvaso dpi

veletri